Budesonide and formoterol in a single pressurized metered-dose inhaler for treatment of COPD

References

• Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet349, 1498–1504 (1997).
   PubMed Web of Science ®Google Scholar
• Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc.4, 554–564 (2007).
   PubMedGoogle Scholar
• Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax57, 847–852 (2002).
   PubMed Web of Science ®Google Scholar
• Stevenson NJ, Walker PP, Costello RW et al. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.172, 1510–1516 (2005).
   PubMed Web of Science ®Google Scholar
• Spencer S, Jones PW; GLOBE study group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax58, 589–593 (2003).
   PubMed Web of Science ®Google Scholar
• Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax60, 925–993 (2005).
   PubMed Web of Science ®Google Scholar
• Cooper CB, Tashkin DP. Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease. Br. Med. J.330, 640–644 (2005).
   PubMed Web of Science ®Google Scholar
• Sin DD, Finlay A, McAlister SF et al. Contemporary management of chronic obstructive pulmonary disease: Scientific Review. JAMA290, 2301–2312 (2003).
   PubMed Web of Science ®Google Scholar
• Jenkins CR, Gones PW, Calverley PM et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomized, placebo-controlled TORCH study. Respir. Res.10, 59 (2009).
   PubMed Web of Science ®Google Scholar
• Nelson HS, Weiss ST, Bleecker ER et al. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest129, 15–26 (2006).
   PubMed Web of Science ®Google Scholar
• Mann M, Chowdhury B, Sullivan E et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest124, 70–74 (2003).
   PubMed Web of Science ®Google Scholar
• Donnelly R, Seale JP. Clinical pharmacokinetics of inhaled budesonide. Clin. Pharmacokinet.40, 427–440 (2001).
   PubMed Web of Science ®Google Scholar
• Zhang M, Fawcett JP, Shaw JP. Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human. Br. J. Clin. Pharmacol.54, 246–250 (2002).
   PubMedGoogle Scholar
• Szafranski W, Cukier A, Ramirez A et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J.21, 74–81 (2003).
   PubMed Web of Science ®Google Scholar
• Calverley PM, Boonsawat W, Cseke Z et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J.22, 912–919 (2003).
   PubMed Web of Science ®Google Scholar
• Eklund A, Tronde A, Jonannes-Hellberg I et al. Pharacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: four open-label, randomized, crossover studies in healthy adults. Biopharm. Drug Dispos.29, 382–395 (2008).
   PubMedGoogle Scholar
• Tronde A, Gillen M, Borgstrom L et al. Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD. J. Clin. Pharacol.48, 1300–1308 (2008).
   PubMedGoogle Scholar
• Chambers F, Ludzik A. In vitro drug delivery performance of a new budesonide/formoterol pressurinzed metered-dose inhaler. J. Aerosol Med. Pulm. Drug Deliv.22, 113–120 (2009).
   PubMedGoogle Scholar
• Miller CJ, Senn S, Mezzanotte WS. Bronchodilation of formoterol administered with budesonide: device and formulation effects. Contemp. Clin. Trials29, 114–124 (2008).
   PubMedGoogle Scholar
• Bousquet J, Huchon G, Leclerc V et al. A randomized, double-blind, double-dummy, single-dose, efficacy crosover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer™) and placebo (pMDI or Aerolizer™) in asthmatic patients. Respiration72(Suppl. 1), 6–12 (2005).
   PubMedGoogle Scholar
• Noonan M, Rosenwasser LJ, Martin P et al. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma. A randomized clinical trial. Drugs66, 2235–2254 (2006).
   PubMed Web of Science ®Google Scholar
• Corren J, Korenblat PE, Miller CJ et al. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clin. Ther.29, 823–843 (2007).
   PubMed Web of Science ®Google Scholar
• Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting β-agonists in the treatment of asthma. N. Engl. J. Med.362, 1169–1171 (2010).
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Rennard SI, Martin P et al. Efficacy and tolerability of budesonide and formoterol administered in one pressurized metered-dose inhaler over 6 months in patients with moderate to very severe chronic obstructive pulmonary disease. Drugs68, 1975–2000 (2008).
   PubMed Web of Science ®Google Scholar
• Rennard SI, Tashkin DP, McElhattan J et al. One-year evaluation of the efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease. Drugs69, 549–565 (2009).
   PubMed Web of Science ®Google Scholar
• Leidy NK, Schmier JK, Jones MKC et al. Evaluating symptoms in chronic obstructive pulmonary disease: validation of the Breathlessness, Cough and Sputum Scale. Respir. Med.97, S59–S70 (2003).
   PubMed Web of Science ®Google Scholar
• Jones PW, Quirk FH, Baveystock CM et al. A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am. Rev. Respir. Dis.145, 1321–1327 (1992).
   PubMed Web of Science ®Google Scholar
• Shah S, White M, Uryniak T et al. The functionality of a budesonide/formoterol pressurized metered-dose inhaler with an integrated actuation counter. Allergy Asthma Proc.31, 40–48 (2010).
   PubMed Web of Science ®Google Scholar
• Melani AS, Zanchetta Z, Sestini N et al. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Ann. Allergy Asthma Immunol.93, 439–446 (2004).
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med.356, 775–789 (2007).
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PM, Seemungal TA et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med.177, 19–26 (2008).
   PubMed Web of Science ®Google Scholar
• Ernst P, Gonzalez AV, Brassard P et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am. J. Respir. Crit. Care Med.176, 162–166 (2007).
   PubMed Web of Science ®Google Scholar
• Drummond MB, Dasenbrook EC, Pitz MW et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA300, 2407–2416 (2008).
   PubMed Web of Science ®Google Scholar
• Sin DD, Tashkin D, Zhang X et al. Budesonide and the risk of pneumonia: a pooled analysis of clinical trials. Lancet374, 712–719 (2008).
   Google Scholar
• Esmailpour N, Hogger P, Rohdewald P. Binding of glucocorticoids to human nasal tissue in vitro. Int. Arch. Allergy Immunol.122, 151–154 (2000).
   PubMed Web of Science ®Google Scholar
• Mortimer KJ, Tattersfield AE, Tang Y et al. Plasma concentrations of fluticasone propionate and budesonide following inhalation: effect of induced bronchoconstriction. Br. J. Clin. Pharmacol.64, 439–444 (2007).
   PubMedGoogle Scholar
• Welte T, Miravitlles M, Hernandez P et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.180, 741–750 (2009).
   PubMed Web of Science ®Google Scholar
• Dahl R, Fan Chung K, Buhl R et al. Efficacy of a new once-daily LABA, indacaterol, versus the twice-daily LABA, formoterol, in COPD. Thorax65, 473–479 (2010).
   PubMed Web of Science ®Google Scholar
• Fitzgerald MR, Fox JC. Emerging trends in the therapy of COPD: bronchodilators as mono- and combination therapies. Drug Discov. Today12, 472–478 (2007).
   PubMed Web of Science ®Google Scholar
• Hochrainer D, Holz H, Kreher C et al. Comparison if the aerosol velocity and spray duration of Respimat® Soft Mist® Inhaler and pressurized metered dose inhalers. J. Aerosol Med.18, 273–282 (2005).
   PubMedGoogle Scholar
• Bateman E, Tashkin D, Siafakas N et al. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir. Med.104(10), 1460–1472 (2010).
   PubMed Web of Science ®Google Scholar
• Nathan RA, Nolte H, Pearlman DS et al. Twenty-six week efficacy and safety study of mometasone furoate/formoterol 200/10 µg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids. Allergy Asthma Proc.31, 269–279 (2010).
   PubMed Web of Science ®Google Scholar
• Weinstein SF, Corren J, Murphy K et al. Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 and 400/10 µg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids. Allergy Asthma Proc.31, 280–289 (2010).
   PubMed Web of Science ®Google Scholar
• Seifart C, Vogelmeier C. Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg. Drugs14, 181–194 (2009).
   PubMed Web of Science ®Google Scholar
• Calverley PM, Rabe KF, Godhring UM et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease: two randomized clinical trials. Lancet374, 685–694 (2009).
   PubMed Web of Science ®Google Scholar
• Fabbri LM, Calverley PM, Izquierdo-Alonso JL et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomized clinical trials. Lancet374, 695–703 (2009).
   PubMed Web of Science ®Google Scholar